Small nucleolar RNA host gene 18 controls vascular smooth muscle cell contractile phenotype and neointimal hyperplasia

Abstract Aims Long non-coding RNA (LncRNA) small nucleolar RNA host gene 18 (SNHG18) has been widely implicated in cancers. However, little is known about its functional involvement in vascular diseases. Herein, we attempted to explore a role for SNHG18 in modulating vascular smooth muscle cell (VSMC) contractile phenotype and injury-induced neointima formation. Methods and results Analysis of single-cell RNA sequencing and transcriptomic datasets showed decreased levels of SNHG18 in injured and atherosclerotic murine and human arteries, which is positively associated with VSMC contractile genes. SNHG18 was upregulated in VSMCs by TGFβ1 through transcription factors Sp1 and SMAD3. SNHG18 gene gain/loss-of-function studies revealed that VSMC contractile phenotype was positively regulated by SNHG18. Mechanistic studies showed that SNHG18 promotes a contractile VSMC phenotype by up-regulating miR-22-3p. SNHG18 up-regulates miR-22 biogenesis and miR-22-3p production by competitive binding with the A-to-I RNA editing enzyme, adenosine deaminase acting on RNA-2 (ADAR2). Surprisingly, we observed that ADAR2 inhibited miR-22 biogenesis not through increasing A-to-I editing within primary miR-22, but by interfering with the binding of microprocessor complex subunit DGCR8 to primary miR-22. Importantly, perivascular SNHG18 overexpression in the injured vessels dramatically up-regulated the expression levels of miR-22-3p and VSMC contractile genes, and prevented injury-induced neointimal hyperplasia. Such modulatory effects were reverted by miR-22-3p inhibition in the injured arteries. Finally, we observed a similar regulator role for SNHG18 in human VSMCs and a decreased expression level of both SNHG18 and miR-22-3p in diseased human arteries; and we found that the expression level of SNHG18 was positively associated with that of miR-22-3p in both healthy and diseased human arteries. Conclusion We demonstrate that SNHG18 is a novel regulator in governing VSMC contractile phenotype and preventing injury-induced neointimal hyperplasia. Our findings have important implications for therapeutic targeting snhg18/miR-22-3p signalling in vascular diseases.

[1]  Q. Xiao,et al.  Noncoding RNAs in Vascular Cell Biology and Restenosis , 2022, Biology.

[2]  V. Paloschi,et al.  Long non-coding RNAs at the crossroad of vascular smooth muscle cell phenotypic modulation in atherosclerosis and neointimal formation. , 2022, Atherosclerosis.

[3]  Xinyong Cai,et al.  The potential function of SP1 and CPPED1 in restenosis after percutaneous coronary intervention , 2022, Journal of cardiac surgery.

[4]  C. Zeng,et al.  LncRNA PSR Regulates Vascular Remodeling Through Encoding a Novel Protein Arteridin , 2022, Circulation research.

[5]  M. Giacca,et al.  Small non-coding RNA therapeutics for cardiovascular disease , 2022, European heart journal.

[6]  M. O’Connell,et al.  ADAR2 enzymes: efficient site-specific RNA editors with gene therapy aspirations , 2022, RNA.

[7]  S. Engelhardt,et al.  MicroRNAs as therapeutic targets in cardiovascular disease , 2022, The Journal of clinical investigation.

[8]  T. Quertermous,et al.  Smad3 regulates smooth muscle cell fate and mediates adverse remodeling and calcification of the atherosclerotic plaque , 2022, Nature Cardiovascular Research.

[9]  Peng-Xia Zhang,et al.  Downregulated lncRNA SNHG18 Suppresses the Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma and Meditates the Antitumor Effect of Oleanolic Acid , 2022, Cancer management and research.

[10]  Quanfeng Ma,et al.  E2F transcription factor 1/small nucleolar RNA host gene 18/microRNA-338-5p/forkhead box D1: an important regulatory axis in glioma progression , 2021, Bioengineered.

[11]  C. Cannon,et al.  Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis , 2021, JACC. CardioOncology.

[12]  A. Vazdarjanova,et al.  CARMN Is an Evolutionarily Conserved Smooth Muscle Cell–Specific LncRNA That Maintains Contractile Phenotype by Binding Myocardin , 2021, Circulation.

[13]  M. Reilly,et al.  Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization , 2021, Circulation.

[14]  Qingbo Xu,et al.  Nonbone Marrow CD34+ Cells Are Crucial for Endothelial Repair of Injured Artery , 2021, Circulation research.

[15]  Dafeng Yang,et al.  A Smooth Muscle Cell–Enriched Long Noncoding RNA Regulates Cell Plasticity and Atherosclerosis by Interacting With Serum Response Factor , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Kun Sun,et al.  Neutrophil elastase promotes neointimal hyperplasia by targeting toll‐like receptor 4 (TLR4)–NF‐κB signalling , 2021, British journal of pharmacology.

[17]  P. Evans,et al.  Cezanne is a critical regulator of pathological arterial remodelling by targeting β-catenin signalling , 2021, Cardiovascular research.

[18]  G. Song,et al.  A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects , 2021, Frontiers in Oncology.

[19]  A. Kourtidis,et al.  LNCcation: lncRNA localization and function , 2021, The Journal of cell biology.

[20]  Yaqing Li,et al.  MKL1-induced lncRNA SNHG18 drives the growth and metastasis of non-small cell lung cancer via the miR-211-5p/BRD4 axis , 2021, Cell death & disease.

[21]  Feng Yang,et al.  miR-214-3p-Sufu-GLI1 is a novel regulatory axis controlling inflammatory smooth muscle cell differentiation from stem cells and neointimal hyperplasia , 2020, Stem cell research & therapy.

[22]  Mei Yang,et al.  miRNA‐200c‐3p promotes endothelial to mesenchymal transition and neointimal hyperplasia in artery bypass grafts , 2020, The Journal of pathology.

[23]  Mingyao Li,et al.  Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human , 2020, Circulation.

[24]  D. Milewicz,et al.  In Vitro Lineage-Specific Differentiation of Vascular Smooth Muscle Cells in Response to SMAD3 Deficiency , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Q. Xiao,et al.  Noncoding RNAs in vascular smooth muscle cell function and neointimal hyperplasia , 2020, The FEBS journal.

[26]  S. Dimmeler,et al.  Noncoding RNAs in Vascular Diseases , 2020, Circulation research.

[27]  T. Thum,et al.  Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease , 2020, Circulation research.

[28]  Xiao-bo Li,et al.  Long Noncoding Ribonucleic Acid SNHG18 Promotes Glioma Cell Motility via Disruption of α-Enolase Nucleocytoplasmic Transport , 2019, Front. Genet..

[29]  Yanping Ma,et al.  High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma , 2019, Acta Haematologica.

[30]  L. Maegdefessel,et al.  Non-coding RNAs in cardiovascular cell biology and atherosclerosis. , 2019, Cardiovascular research.

[31]  Delphine Gomez,et al.  Smooth Muscle Cell Phenotypic Diversity. , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[32]  I. Ulitsky,et al.  The Human-Specific and Smooth Muscle Cell-Enriched LncRNA SMILR Promotes Proliferation by Regulating Mitotic CENPF mRNA and Drives Cell-Cycle Progression Which Can Be Targeted to Limit Vascular Remodeling , 2019, Circulation research.

[33]  Feng Yang,et al.  Macrophage-derived MMP-8 determines smooth muscle cell differentiation from adventitia stem/progenitor cells and promotes neointima hyperplasia. , 2019, Cardiovascular research.

[34]  Rory Johnson,et al.  Global Positioning System: Understanding Long Noncoding RNAs through Subcellular Localization. , 2019, Molecular cell.

[35]  E. Low,et al.  TGFβ, smooth muscle cells and coronary artery disease: a review , 2019, Cellular signalling.

[36]  J. Tu,et al.  Small Nucleolar RNA Host Gene 18 Acts as a Tumor Suppressor and a Diagnostic Indicator in Hepatocellular Carcinoma , 2018, Technology in cancer research & treatment.

[37]  J. Lima,et al.  Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment: Together We Are Stronger , 2018, Circulation.

[38]  M. Bendeck,et al.  Role of smooth muscle cells in coronary artery bypass grafting failure. , 2018, Cardiovascular research.

[39]  Jacob F Bentzon,et al.  Lineage tracking of origin and fate of smooth muscle cells in atherosclerosis. , 2018, Cardiovascular research.

[40]  A. Avolio,et al.  Smooth muscle cell and arterial aging: basic and clinical aspects , 2018, Cardiovascular research.

[41]  S. Allahverdian,et al.  Smooth muscle cell fate and plasticity in atherosclerosis , 2018, Cardiovascular research.

[42]  M. Bennett,et al.  Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis , 2018, Cardiovascular research.

[43]  D. Milewicz,et al.  From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta , 2018, Cardiovascular research.

[44]  N. Leeper,et al.  Non-coding RNAs: key regulators of smooth muscle cell fate in vascular disease , 2018, Cardiovascular research.

[45]  A. Durham,et al.  Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness , 2018, Cardiovascular research.

[46]  R. Houlgatte,et al.  Identification of genomic differences among peripheral arterial beds in atherosclerotic and healthy arteries , 2018, Scientific Reports.

[47]  Mei Yang,et al.  Cbx3 inhibits vascular smooth muscle cell proliferation, migration, and neointima formation , 2018, Cardiovascular research.

[48]  Feng Yang,et al.  miR-22 Is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation , 2017, Circulation.

[49]  Qingbo Xu,et al.  Novel Pathological Role of hnRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) in Vascular Smooth Muscle Cell Function and Neointima Hyperplasia , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[50]  N. Sarrafzadegan,et al.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. , 2017, Atherosclerosis.

[51]  P. Cutillas,et al.  NCK Associated Protein 1 Modulated by miRNA‐214 Determines Vascular Smooth Muscle Cell Migration, Proliferation, and Neointima Hyperplasia , 2016, Journal of the American Heart Association.

[52]  Y. Liu,et al.  Upregulation of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 Promotes Radioresistance of Glioma by Repressing Semaphorin 5A. , 2016, International journal of radiation oncology, biology, physics.

[53]  Thorsten Stafforst,et al.  Harnessing human ADAR2 for RNA repair – Recoding a PINK1 mutation rescues mitophagy , 2016, Nucleic acids research.

[54]  D. Zheng,et al.  MYOSLID Is a Novel Serum Response Factor–Dependent Long Noncoding RNA That Amplifies the Vascular Smooth Muscle Differentiation Program , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[55]  Ling-Ling Chen.  Linking Long Noncoding RNA Localization and Function. , 2016, Trends in biochemical sciences.

[56]  N. Sattar,et al.  Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation , 2016, Circulation.

[57]  A. Blaes,et al.  Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.

[58]  M. Bennett,et al.  Vascular Smooth Muscle Cells in Atherosclerosis. , 2016, Circulation research.

[59]  K. Nishikura,et al.  A-to-I editing of coding and non-coding RNAs by ADARs , 2015, Nature Reviews Molecular Cell Biology.

[60]  Feng Yang,et al.  miRNA-34a reduces neointima formation through inhibiting smooth muscle cell proliferation and migration. , 2015, Journal of molecular and cellular cardiology.

[61]  E. Eisenberg,et al.  Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma , 2015, Genome Biology.

[62]  A. von Haeseler,et al.  ADAR2 induces reproducible changes in sequence and abundance of mature microRNAs in the mouse brain , 2014, Nucleic acids research.

[63]  D. Zheng,et al.  Identification and Initial Functional Characterization of a Human Vascular Cell–Enriched Long Noncoding RNA , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[64]  Qingbo Xu,et al.  Matrix Metalloproteinase-8 Promotes Vascular Smooth Muscle Cell Proliferation and Neointima Formation , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[65]  Fritz J Sedlazeck,et al.  Adenosine deaminases that act on RNA induce reproducible changes in abundance and sequence of embryonic miRNAs , 2012, Genome research.

[66]  G. Owens,et al.  Smooth muscle cell phenotypic switching in atherosclerosis. , 2012, Cardiovascular research.

[67]  O. Abdel-Wahab,et al.  Faculty Opinions recommendation of lincRNAs act in the circuitry controlling pluripotency and differentiation. , 2011 .

[68]  B. Davis-Dusenbery,et al.  Down-regulation of Krüppel-like Factor-4 (KLF4) by MicroRNA-143/145 Is Critical for Modulation of Vascular Smooth Muscle Cell Phenotype by Transforming Growth Factor-β and Bone Morphogenetic Protein 4* , 2011, The Journal of Biological Chemistry.

[69]  G. Wang,et al.  Sp1-dependent Activation of HDAC7 Is Required for Platelet-derived Growth Factor-BB-induced Smooth Muscle Cell Differentiation from Stem Cells* , 2010, The Journal of Biological Chemistry.

[70]  Donghong Ju,et al.  Disruption of actin cytoskeleton mediates loss of tensile stress induced early phenotypic modulation of vascular smooth muscle cells in organ culture. , 2010, Experimental and molecular pathology.

[71]  M. O’Connell,et al.  Editing independent effects of ADARs on the miRNA/siRNA pathways , 2009, The EMBO journal.

[72]  Michael F. Lin,et al.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals , 2009, Nature.

[73]  Chunxiang Zhang,et al.  Serum deprivation results in redifferentiation of human umbilical vascular smooth muscle cells. , 2006, American journal of physiology. Cell physiology.

[74]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[75]  G. Owens,et al.  Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. , 2000, The Journal of clinical investigation.

[76]  S. Sims,et al.  Evidence from a novel human cell clone that adult vascular smooth muscle cells can convert reversibly between noncontractile and contractile phenotypes. , 1999, Circulation research.

[77]  S. Rensen,et al.  Cultured porcine coronary artery smooth muscle cells. A new model with advanced differentiation. , 1999, Circulation research.

[78]  R. S. Blank,et al.  Platelet-derived growth factor-BB-induced suppression of smooth muscle cell differentiation. , 1992, Circulation research.

[79]  P. Seeburg,et al.  Modulation of microRNA processing and expression through RNA editing by ADAR deaminases , 2006, Nature Structural &Molecular Biology.

[80]  S. R. Grant,et al.  Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. , 2005, The Journal of biological chemistry.